Anti-MAGEA1 antibody [SP194] - C-terminal,Abcam,AB183309

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

WB, Flow Cyt (Intra), IHC-P

Platform ID

BAB064756931

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-MAGEA1 antibody [SP194] - C-terminal
Cat. No.AB183309
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationWB, Flow Cyt (Intra), IHC-P
ClonalityMonoclonal
Clone NumberSP194
Concentration0.157 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A/G
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.6 Preservative: 0.1% Sodium azide Constituents: PBS, 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data May be involved in transcriptional regulation through interaction with SNW1 and recruiting histone deactelyase HDAC1. May inhibit notch intracellular domain (NICD) transactivation. May play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. See full target information MAGEA1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.